Genmab presented clinical updates on petosemtamab, an investigational bispecific antibody, in two major solid tumor types at the European Society for Medical Oncology Congress 2026. The updates increased investor optimism. Genmab also secured a clinical oncology collaboration with Incyte.
Genmab presented updated Phase 2 results on Monday for petosemtamab combined with pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma. The combination achieved median overall survival of 28.2 months. The overall response rate reached 63%, with complete responses in 19% of evaluable patients. Median progression-free survival reached 9.0 months. An estimated 55% of responders retained a clinical response at 24 months.
Investigators found consistent antitumor activity across PD-L1 expression levels and p16 subgroups. The study recorded neither Grade 5 adverse events nor treatment-related deaths. Genmab is advancing a global Phase 3 trial in this setting. Genmab expects topline results later this year.
Genmab reported updated Phase 2 findings on Sunday for petosemtamab combined with standard FOLFOX or FOLFIRI chemotherapy in metastatic colorectal cancer. Objective response rates reached 75% in first-line treatment and 67% in second-line treatment. The response rate reached 81% among first-line patients whose tumors were left-sided. Patients with liver metastases achieved response rates of 76% in first-line treatment and 67% in second-line treatment. Disease control rates in the first-line and second-line settings reached 95% and 93%, respectively. Adverse events led 5% of mFOLFOX6 patients and 3% of FOLFIRI patients to discontinue treatment. The combinations caused no treatment-related deaths.
Genmab announced the Incyte clinical trial collaboration on Friday for first-line metastatic colorectal cancer with KRAS G12D mutations. Under the agreement, Genmab will run a Phase 1/2 trial combining petosemtamab, standard chemotherapy and INCB161734, Incyte's selective KRAS G12D candidate. Incyte will contribute funding for the study. Incyte will also supply investigational drugs.
Genmab shares traded at $44.93 at publication on Monday, an increase of 1.56%. Benzinga Pro data showed that the shares were trading at a new 52-week high.
Genmab Reports Positive Oncology Data for Petosemtamab in Head and Neck, Colorectal Cancers
BenzingaShare
Summary
Genmab shared updated Phase 2 data for petosemtamab in head and neck and colorectal cancers at ESMO 2026. In head and neck cancer, the combo with pembrolizumab showed 28.2-month median survival and 63% response rate. Colorectal results hit 75% in first-line and 67% in second-line. Genmab also partnered with Incyte for a trial in KRAS G12D metastatic colorectal cancer. With inflation data and interest rate news affecting biotech funding, such results could influence investor sentiment.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.